Kornimate/medical-research-clean huggingface dataset:
prediction of tongue base obstruction during sleep

Conditions: Obstructive Sleep Disordered Breathing

Summary: this study investigates the hypothesis that, in children, tongue motor functions can predict both the anatomical site and the degree of upper airway obstruction contributing to obstructive sleep-disordered breathing.

patients will be enrolled during their visit to the ent physician. subsequently, their tongue motor functions will be assessed during their pre-surgical appointment. finally, they will undergo a drug-induced sleep endoscopy prior to their surgery.

Eligibility criteria:
inclusion criteria: * age between 6 and 17 years old * medical diagnosis of obstructive sleep-disordered breathing requiring surgical removal of tonsils (partial or total) and/or adenoids * positive pediatric sleep questionnaire (8 or more positive responses) * eligibility for surgical intervention exclusion criteria: * neurological, cardiac, or respiratory comorbidity other than obstructive sleep-disordered breathing * previous surgery of the upper airway or oral cavity * history of or current head or neck cancer * cranial, upper airway, or oral cavity malformation * contraindication to performing endoscopy

Keywords: obstructive sleep disordered breathing pediatrics sleep obstructive sleep apnea snoring tongue
angiogenesis inhibitor plus anti-pd-1/pd-l1 antibody in advanced esophageal cancer

Conditions: Esophageal Neoplasms

Summary: the combination of an anti-pd-1/pd-l1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.the purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.


Eligibility criteria:
inclusion criteria: 1. esophageal cancer confirmed by histopathology or cytology 2. unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy 3. esophageal cancer patients who benefit from the use of an anti-pd-1/pd-l1 antibody with an angiogenesis inhibitor evaluated by the researchers 4. patients who sign informed consent and voluntarily join the study exclusion criteria: 1. patients who are recommended not using an anti-pd-1/pd-l1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study 2. patients who are undergoing treatment regimen of blind trial
profile of copd patients refusing educational program in pulmonary rehabilitation and impact on the benefits

Conditions: Chronic Obstructive Pulmonary Disease; Pulmonary Rehabilitation

Summary: pulmonary rehabilitation (pr) has proven its efficacy to improve dyspnea, health status, exercise tolerance and quality of life for patients with stable chronic obstructive pulmonary disease (copd). exercise training has previously been thoroughly studied but education has been less studied in pr. furthermore, only few studies have investigated the added value of an educational program (ep) to exercise training on clinical and physical factors. characterizing those patients who refuse ep is therefore a first step to better target them and potentially improve their adherence and outcome following pr. the aim of this study was to determine the characteristics of the copd patients referred to pr who refused ep compare to those who accepted and to identify the independent predictive factors of refusal. the investigators also sought to compare the change in clinical outcomes and number and length of hospitalization at six months following pr among those patients who accepted or not to participate in ep.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd, * \>18 years old, * stable state of copd. exclusion criteria: * patients who have not been offered an educational program * patients who have already been offered an educational program during a pulmonary rehabilitation in the same center.

Keywords: chronic obstructive pulmonary disease pulmonary rehabilitation education
sexual functions and marital adjustment for spouses in menopause

Conditions: Menopause

Summary: objective: this study was conducted as a cross-sectional descriptive study in order to determine the effect of menopause on the sfs and marital adjustment of the spouses.

objective: this study was conducted as a cross-sectional descriptive study in order to determine the effect of menopause on the sfs and marital adjustment of the spouses. materials and methods: the sample of the study consisted of a total of 254 people, 127 of whom were postmenopausal women and their spouses. the data were collected with the descriptive information form (dif), the female sexual function scale (fsfs) and the arizona sexual experiences scale (ases), the marital adjustment scale (mas). t test was used for two-group comparison of parametric data, mann whitney u test was used for two-group comparison of non-parametric data, and kruskal wallis test was used for non-parametric data comparison of more than two groups. in addition, the relationship between the mean scores of fsfs, ases and mas was evaluated with spearman's rho correlation analysis.

Eligibility criteria:
inclusion criteria: * the sample of the study consisted of women aged between 45-65, * who were aged between 45-65, * had at least 1 year of menopause, * had no communication barriers, * volunteered to participate in the research, -lived in the same house with their spouses, - * had sexual activity in the last four weeks, * selected using the simple random sampling method. exclusion criteria: * have diabetes, * have hypertension, * have depression
assessment of low level laser therapy for late postoperative pain after lumbar fusion surgery

Conditions: Surgery

Summary: the primary objective of this study is to assess whether or not low level laser therapy (lllt) decreases pain in post-operative orthopedic patients following lumbar fusion surgery.

lumbar fusion surgery patients typically experience significant post-operative pain for several weeks and their rehabilitation does not start until 8 - 12 weeks postoperatively. we hypothesize that lllt beginning 4 weeks postoperatively will provide significant reduction in postoperative pain.

Eligibility criteria:
inclusion criteria * age \> 18 and \< 85 years * post-operative lumbar fusion surgery * currently resides within 100 miles of umc exclusion criteria * pregnant * pacemaker * medications that have heat or light-sensitivity contraindications (such as: steroids, some antibiotics) * two or more cardiac risk factors * intraoperative complications * wound infection * spinal fluid leakage * open wound
a study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (stop-v1)

Conditions: NonSegmental Vitiligo

Summary: this study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years. * clinical diagnosis of nonsegmental vitiligo and meet the following: * t-bsa ≥ 5% * t-vasi score ≥ 4 * f-bsa ≥ 0.5% * f-vasi score ≥ 0.5 * agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit. * willingness to avoid pregnancy or fathering children. exclusion criteria: * other forms of vitiligo or skin depigmentation disorders. * clinically significant abnormal tsh or free t4 at screening. * use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to day 1. * current or past use of the depigmenting agent monobenzyl ether of hydroquinone including benoquin®. * history of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo. * spontaneous and significant repigmentation within 6 months prior to screening. * women who are pregnant, considering pregnancy, or breast feeding. * medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies. * evidence of infection with tb, hbv, hcv or hiv. * history of failure to jak inhibitor treatment of any inflammatory disease. * laboratory values outside of the protocol-defined ranges. other protocol-defined inclusion/exclusion criteria may apply.
treatment of diabetic neuropathy with liraglutide

Conditions: Diabetes Mellitus, Type 1; Type 1 Diabetes Mellitus

Summary: the purpose of this trial is to explore whether liraglutide has a long term effect on clinical symptoms and biomarkers in patients with diabetic neuropathy.


Eligibility criteria:
inclusion criteria: * abile person of northern european descent * age between 18 to 65 years * a verified diagnosis of dm type 1 for minimum 2 years (hba1c=7%) * stable dm treatment (treatment is considered stable when the patient has been treated with basal-bolus insulin, premixed insulin or continously infused insulin with an insulin dose considered stable by investigator for at least 3 months prior to screening.) * the participants must be able to read and understand danish. * peripheral diabetic neuropathy ensured by having abnormal nerve conduction velocity * bmi equal to or above 22 * personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial. * patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other trial procedures. exclusion criteria: * diabetes mellitus type ii * estimated glomerular filtration rate (s-creatinin/egrf) \< 60 ml/min/1.37m2 * calcitonin \> 25 * hba1c level \< 7% * patients with any clinically significant laboratory abnormalities, that in the opinion of the investigator may increase the risk associated with trial participation or may interfere with the interpretation of the trial results. * patients on glp-1 receptor agonist treatment (exenatide, liraglutide or others) or pramlintide or any dpp-4 inhibitor within 3 months prior to screening. * other neurological and/or psychiatric disease * treatment of other endocrinological disease except hypothyreosis * malignant neoplasms requiring chemotherapy, surgery, radiation or palliative care in the previous 5 years. * family or personal history of multiple endocrine neoplasia type 2 (men2) or familial medullary thyroid carcinoma. * personal history of non-familial medullary thyroid carcinoma * known abuse or alcohol and/or medicine (alcohol use in accordance with the recommendations by the danish health and medicines authority are allowed). * known allergy to liraglutide. * participation in other clinical trials less than 3 months prior to inclusion * female patients who are pregnant or lactating, or intend to become pregnant and male patients who intend to father a child during course of the study. * in women, a serum pregnancy test will be conducted at baseline based on h-cg in the blood. the investigator will have to ensure that fertile female patients use a safe contraception method during the study and for at least 15 hours after termination of the study medication period.

Keywords: diabetes mellitus, type 1 diabetic neuropathy liraglutide
meditoxin® treatment in subject with benign masseteric hypertrophy

Conditions: Masseter Muscle Hypertrophy

Summary: to evaluate the efficacy and safety of meditoxin in subjects with benign masseteric hypertrophy compared with placebo


Eligibility criteria:
inclusion criteria: * subject who aged 20 to less than 65 years * subject with benign masseteric hypertrophy exclusion criteria: * subject not appropriate for participating in this study according to the investigator's opinion * subject with known an anaphylactic response to bont/a and other involved ingredients of investigational product
transthyretin amyloidosis outcome survey (thaos)

Conditions: Transthyretin Gene Mutations; Transthyretin Amyloidosis

Summary: thaos is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (attr), including attr-pn (polyneuropathy), attr-cm (cardiomyopathy) and wild-type attr-cm. it is open-ended with a minimum duration of 10 years. patients will be followed as long as they are able to participate. the principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.

n/a na

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for inclusion into thaos: 1. evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study. 2. males and females greater than or equal to 18 years of age. 3. confirmed genotyped ttr mutation with or without a diagnosis of hereditary or wild-type attr amyloidosis. confirmation of attrwt amyloidosis will be determined by genotyped confirmation that patient does not possess a known mutation in ttr gene (ie, is a carrier of wild-type allele only) via genetic testing and one of the following set of criteria (a, b, or c): 1. presence of amyloid in cardiac biopsy tissue confirmed as ttr amyloid by mass spectrometry or immunohistochemistry; or 2. evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of \>12 mm, and presence of amyloid in non-cardiac tissue confirmed as ttr amyloid by mass spectrometry or immunohistochemistry; or 3. evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of \>12 mm, and presence of amyloid in cardiac tissue indirectly confirmed by scintigraphy with a "bone seeking tracer" eg, 99mtc-dpd \[99mtc-3,3-diphosphono-1,2-propano-dicarboxylic acid\], 99mtc- pyp \[pyrophosphate\], and 99mtc-hmdp \[hydroxymethylene diphosphonate\] with perugini grade greater than or equal to 2. exclusion criteria patients meeting any of the following will not be included in the study: 1. patient has evidence of primary (light chain) or secondary amyloidosis.

Keywords: transthyretin amyloidosis transthyretin amyloidosis transthyretin amyloid cardiomyopathy
impact of bariatric surgery on heart disease compared to standard care

Conditions: Obesity, Morbid; Bariatric Surgery Candidate; Heart Diseases

Summary: obesity is associated with type 2 diabetes (t2d) and cardiovascular disease (cvd). metabolic and bariatric surgery (mbs) has in several randomized controlled trials (rct) been shown to be superior to best medical therapy in the treatment of t2d. in the area of cvd, rct after mbs are lacking. it was recently demonstrated in a cohort study that mbs in patients with severe obesity and a previous myocardial infarction (mi) was associated with a 50% reduction in the risk of death and new mi. the aim of this proposal is to confirm this in a nationwide rct. using the nationwide swedeheart database patients with severe obesity and a previous mi will be identified. they will be contacted and offered participation. after informed consent the patients will be randomized to mbs or optimized care (including visit with a cardiologist and optimization of secondary preventive measures and referral to dietician/physiotherapist). the primary outcome measure is a major cardiovascular adverse event (mace). secondary outcome measures include mortality, new mi, stroke, heart failure and atrial fibrillation. tertiary outcome measures include health related quality of life and surgical complications. patients will be followed in the nationwide metabolic surgery register soreg, the national inpatient register, national cause of death register, the swedish prescribed drug register, and the swedish population register. if positive results these can be included in guidelines for mbs.


Eligibility criteria:
inclusion criteria: * mi (as defined by the universal definition of mi) at least 1 year before inclusion. * bmi ≥35 kg/m2 * written informed consent obtained exclusion criteria: * any condition that may influence the patient's ability to comply with study protocol. * earlier mbs or operation for gastric or duodenal ulcer or reflux disease * other condition that makes patient not suitable for mbs according to responsible surgeon and anesthesiologist * unable to understand swedish.
genetics of motor learning

Conditions: Parkinson s Disease; Dystonic Disorders; Focal Dystonia; Movement Disorders

Summary: background: - new studies in human genetics have revealed information about genetic connections to memory and motor behavior. researchers are interested in investigating the role of genetics in motor learning, in conjunction with related studies taking place in the human motor control section of the national institute of neurological diseases and stroke (ninds). participants in motor learning studies conducted at ninds will be asked to provide blood samples for further evaluation. objectives: - to create a repository of blood samples from patients and healthy subjects who are participating in ninds motor learning studies. eligibility: - individuals between 18 and 100 years of age who are or will be participating in motor learning research studies at the national institutes of health. design: * blood draws for genetic testing will usually be done on the same day as the motor learning study. participants will provide one blood sample for research. * no treatment will be provided under this study....

objective:\ the objective of this study is to create a bio-repository of blood samples from patients and healthy subjects who are participating in ninds motor learning studies. blood will be analyzed for bdnf and samples stored for future genetic studies. . a variety of genes that may affect motor learning are being increasingly identified, and variations among these genes, referred to as polymorphisms, may help explain individual differences. study population: \ we will enroll up to five hundred healthy volunteers and five hundred volunteers with movement difficulties who are between the ages of 18 and 100 and who are already participating, or will be participating, in other protocols dealing with motor learning research studies at the national institutes of health (nih). design:\ this is an observational and repository protocol that involves a single blood sample for genetic analysis. this will allow the genetic characterization of subjects participating in motor learning protocols to be analyzed and tested for the role of genetics in motor learning results. outcome measure: we will compare genetic variations with the different behavioral, electrophysiologic, imaging, or other outcomes acquired in the associated motor learning studies. thus, we will determine whether specific polymorphisms are associated with different measures of motor learning.

Eligibility criteria:
* inclusion criteria: \ anyone aged 18-100 years and participating in a motor learning study at nih is eligible to participate in this study. \ exclusion criteria: anyone with impaired decisional capacity, inability to provide informed consent, or who is unable to safely give blood is not eligible to participate in this study.

Keywords: motor learning genetic analysis bdnf parkinson disease movement disorders dystonia healthy volunteer hv
educational training influence in patients with pah(pulmonary artery hypertension) on inhaled ventavis treatment adherence evaluated trough insight system

Conditions: Pulmonary Arterial Hypertension

Summary: ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called i-neb. in these patients, the non compliance of the treatment becomes its ineffective and increases the complications and mortality of the disease. it is therefore important to know which the adherence of patients to their treatment is and try to promote it. one possibility to reach a good level of adherence is the patient education regarding the drug administration and also to comply as better is possible the recommendations of the physician. for this reason, the objective of our study is to demonstrate improvement in the level of treatment compliance when they follow a strategy of continuing education, assessed by the device and software called insight. the only special procedure to participate in the study then is that patients involved could receive more training than usual. investigators expect involving in this study around 50 patients in treatment with ventavis and diagnosed of pulmonary arterial hypertension in 10-12 hospitals throughout spain. the patients who participated in the study will be followed for 12 months from inclusion in the study and will perform around 5 visits in total.


Eligibility criteria:
inclusion criteria: * male or female patients \> 18 years of age. * patients in new york heart association (nyha) functional class ii-iv pulmonary hypertension who are treated with ventavis at least three months before and who use -neb ® aad ® system. * patients who accepted participation in the study and sign informed consent. * patients with ability to understand and follow the instructions and are able to participate for the duration of the study. exclusion criteria: * patients with severe cognitive impairment. * geographically unstable patients who can not be followed during the 12 month study. * patients who have a life expectancy of at least 12 months. * patients who are participating in another study at the time of inclusion. .

Keywords: education ventavis adherence pah pulmonary artery hypertension